Alberta Blue Cross’s recent decision to include psychedelic-assisted therapy in their healthcare coverage marks a transformative moment in the perception...
VANCOUVER, BC, April 3, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage...
MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to...
Filament and Jaguar have been importing coca leaves into Canada. The post Filament’s pivots pay off, nets $2.1M revenue in 2023 appeared first on Green...
OTTAWA, April 02, 2024 (GLOBE NEWSWIRE) — PsyCan, the not-for-profit trade association for the legal Canadian psychedelic medicine industry, welcomes...
VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:...
The upcoming study will compare the effects of DMT and a placebo in stroke patients. The post Algernon sells Ifenprodil, zooms in on DMT for stroke...
NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical...
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed...
The firm said it feels comfortable about its runway through 2026. The post Atai cash purse down nearly half despite lower spending appeared first on Green...